**Latent Autoimmune Diabetes in Adults (LADA)- An insight into early diagnosis and management**

Dr. Kamna Singh, Dr. Pranay Chakotiya, Dr. Richa Gupta, Dr. Vikas Kumar

1. Associate Professor and Head, Department of Biochemistry, SNMC Agra

<https://orcid.org/0000-0002-4934-36>83

1. Assistant Professor, Department of Plastic Surgery, SNMC Agra
2. Associate Professor and Head, Department of Forensic Medicine and Toxicology, SNMC Agra

<https://orcid.org/0000-0002-2379-1672>

1. Associate Professor, Department of Microbiology, SNMC Agra

<https://orcid.org/0000-0002-4787-62>24

**Abstract:**

Latent Autoimmune Diabetes in Adults (LADA) is a unique form of diabetes characterized by the presence of autoimmune markers, resembling features of both type 1 and type 2 diabetes. LADA patients have functioning beta cells at diagnosis, necessitating therapeutic strategies that aim to improve metabolic control and preserve insulin-secreting capacity. The presence of glutamic acid decarboxylase 65 autoantibodies (GADA) is a hallmark of LADA, along with other less frequent autoantibodies. Genetic susceptibility overlaps with type 1 diabetes, including specific HLA genes and polymorphisms within insulin and protein-tyrosine-phosphatase nonreceptor 22 (PTPN22) genes. Management of LADA involves early recognition, lifestyle modifications, and judicious use of hypoglycemic agents such as insulin sensitizers and dipeptidyl peptidase 4 inhibitors (DPP-4i). Individualized care and regular monitoring are essential to optimize glycemic control and preserve beta-cell function in LADA patients.

**Keywords:** Latent Autoimmune Diabetes in Adults, LADA, Autoimmune diabetes, glutamic acid decarboxylase, GADA.

**Introduction:**

Latent Autoimmune Diabetes in Adults (LADA) is a relatively uncommon form of diabetes that shares characteristics with both type 1 diabetes (T1D) and type 2 diabetes (T2D). LADA is often misdiagnosed as T2D due to its gradual onset and occurrence in adulthood, but it has distinct autoimmune features similar to T1D. This unique combination of features has led to LADA being referred to as "type 1.5 diabetes" or "slow-onset type 1 diabetes."

Unlike classic T1D, which typically develops in childhood or adolescence and is characterized by a rapid destruction of insulin-producing beta cells in the pancreas, LADA follows a more gradual and insidious course. Individuals with LADA may initially experience symptoms similar to T2D, such as insulin resistance and elevated blood sugar levels, leading to the initial misclassification. However, over time, the autoimmune process progresses, resulting in a decline in beta cell function and eventual dependence on insulin therapy.

LADA presents diagnostic and therapeutic challenges due to its atypical nature and overlapping features with other forms of diabetes. Early detection and accurate diagnosis of LADA are crucial for providing appropriate management and improving long-term outcomes for affected individuals.

In this article, we will delve into the epidemiology, pathophysiology, clinical manifestations, diagnosis, and treatment of LADA. By understanding the unique features of LADA and its distinctions from other types of diabetes, healthcare professionals can enhance their ability to identify and manage this condition effectively. Additionally, ongoing research into LADA's underlying mechanisms may provide valuable insights into autoimmune diabetes as a whole, potentially paving the way for more personalized and targeted therapies in the future.

**Epidemiology:**

Latent Autoimmune Diabetes in Adults (LADA) is a relatively rare form of diabetes, and its prevalence varies across different populations and regions. As a subtype of diabetes, LADA shares some epidemiological characteristics with both type 1 diabetes (T1D) and type 2 diabetes (T2D).

1. Prevalence:

The prevalence of LADA is estimated to be around 5-10% of all diabetes cases, making it less common than T1D and T2D. However, due to its resemblance to T2D in its early stages, LADA is often misdiagnosed, leading to potential underestimation of its true prevalence.

2. Age of Onset:

LADA typically occurs in adults, and the age of onset is usually between 30 and 50 years, although it can manifest at any age. This differentiates it from classical T1D, which primarily develops in childhood or adolescence, and from T2D, which is more common in middle-aged and older individuals.

3. Autoimmune Component:

LADA is characterized by its autoimmune nature, wherein the body's immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. As a result, the prevalence of autoantibodies, such as GAD65 (glutamic acid decarboxylase) antibodies, is a critical marker for diagnosing LADA. However, the presence of autoantibodies can vary among individuals and populations, making it challenging to accurately estimate the prevalence of LADA based solely on serological testing.

4. Ethnic and Geographic Variation:

LADA's prevalence may differ among ethnic groups and in various geographic regions. Some studies suggest a higher prevalence of LADA in populations with a higher incidence of T1D, whereas others indicate an association with T2D prevalence. Geographical variations and genetic predispositions may also play a role in the differences observed in LADA prevalence.

5. Progression to Insulin Dependency:

As LADA progresses, affected individuals often require insulin therapy due to the gradual decline in beta cell function. However, the rate of progression can vary, and some individuals may maintain sufficient beta cell function for an extended period without insulin therapy.

6. Risk Factors:

Although the exact risk factors for LADA remain incompletely understood, some factors may increase the likelihood of developing this condition. These factors include a family history of autoimmune diseases, certain genetic markers, and the presence of specific autoantibodies.

Overall, understanding the epidemiology of LADA is essential for early detection, accurate diagnosis, and appropriate management of this unique form of diabetes. Given its autoimmune nature and potential for insulin dependence, further research and awareness of LADA are crucial to improving patient outcomes and enhancing our understanding of autoimmune diabetes as a whole.

**Pathophysiology of Latent Autoimmune Diabetes in Adults (LADA):**

Latent Autoimmune Diabetes in Adults (LADA) is a distinct subtype of diabetes that results from an interplay of autoimmune processes and genetic predisposition. The pathophysiology of LADA shares characteristics with both type 1 diabetes (T1D) and type 2 diabetes (T2D), making it a unique and complex condition.

1. Autoimmunity and Beta Cell Destruction:

LADA is characterized by an autoimmune attack on the insulin-producing beta cells in the pancreas. This autoimmune process is driven by the activation of immune cells, such as T lymphocytes, which recognize specific antigens present on the surface of beta cells. One of the primary autoantigens involved in LADA is the glutamic acid decarboxylase 65 (GAD65) enzyme. GAD65 antibodies are commonly detected in individuals with LADA and play a crucial role in the immune-mediated destruction of beta cells.

2. Gradual Onset:

Unlike classic T1D, where the autoimmune attack on beta cells is rapid and aggressive, LADA follows a slower and more insidious course. This gradual progression is one of the reasons why LADA is often misdiagnosed as T2D initially. As the autoimmune process progresses over time, the beta cell mass gradually declines, leading to a decline in insulin production.

3. Insulin Resistance:

In the early stages of LADA, individuals may exhibit features of insulin resistance, a hallmark of T2D. Insulin resistance refers to reduced responsiveness of cells to the action of insulin, leading to decreased glucose uptake and increased blood glucose levels. Insulin resistance contributes to hyperglycemia and compensatory hyperinsulinemia, as the pancreas tries to overcome the resistance by producing more insulin.

4. Beta Cell Dysfunction:

As LADA advances, the combination of autoimmune destruction and insulin resistance results in impaired beta cell function. The remaining beta cells become less effective at producing insulin, further contributing to hyperglycemia and necessitating the eventual need for insulin therapy.

5. Genetic Predisposition:

Genetics also plays a role in LADA development. Specific genetic markers and variants are associated with an increased risk of developing autoimmune diabetes. Certain human leukocyte antigen (HLA) genes have been linked to an increased susceptibility to LADA, similar to their involvement in T1D. However, the genetic contributions to LADA are not as clear-cut as in T1D, as some individuals may possess genetic risk factors associated with both LADA and T2D.

6. Overlapping Features:

The complex nature of LADA makes it challenging to distinguish from T1D and T2D, as it shares features of both conditions. This overlap in pathophysiology and clinical presentation often leads to misdiagnosis or delayed diagnosis, which can impact treatment decisions and patient outcomes.

**Characteristics of LADA:**

**i) Phenotypical Features:**

1. Age at Diagnosis: Patients with LADA are typically younger at the time of diabetes diagnosis compared to those with antibody-negative type 2 diabetes (T2D).

2. Body Mass Index (BMI): LADA patients generally have a lower BMI at the time of diagnosis compared to individuals with T2D.

3. Family History: LADA patients may have a personal or family history of autoimmune diseases, suggesting a genetic predisposition to autoimmune conditions.

4. Autoantibodies: LADA is characterized by the presence of specific autoantibodies, with glutamic acid decarboxylase 65 autoantibodies (GADA) being the most predominant marker. Other autoantibodies, such as IA-2A, IAA, ZnT8A, and tetraspanin 7, may also be present, although less frequently.

**ii) Autoantibodies:**

1. GADA: Glutamic acid decarboxylase 65 autoantibodies (GADA) are considered the most sensitive marker for LADA and are commonly detected in the majority of LADA patients.

2. Other Autoantibodies: In addition to GADA, LADA patients may have autoantibodies targeting other antigens, including IA-2, insulin, ZnT8, and tetraspanin 7.



**iii) Genetic Susceptibility:**

1. HLA Genes: LADA shares genetic susceptibility with type 1 diabetes (T1D) and is associated with specific polymorphisms within the HLA DQB1 and DRB1 genes, similar to T1D. However, unlike childhood-onset T1D, class I genes (HLA-A and HLA-B) are not strongly associated with LADA.

2. Other Genes: Polymorphisms within genes like insulin and protein-tyrosine-phosphatase nonreceptor 22 (PTPN22) and Src homology 2-B (SH2B3) have also been identified as shared genetic risk factors between LADA and T1D.

 

Figure-1.0 [pathways of latent autoimmune diabetes in adults](https://www.researchgate.net/figure/Potential-pathological-pathways-of-latent-autoimmune-diabetes-in-adults-LADA-Modified_fig2_325968779%22%20%5Ct%20%22_blank)

**Management of Latent Autoimmune Diabetes in Adults (LADA):**

The management of Latent Autoimmune Diabetes in Adults (LADA) requires a comprehensive and individualized approach, considering its unique features that overlap with both type 1 diabetes (T1D) and type 2 diabetes (T2D). The primary goals of LADA management are to control blood glucose levels, prevent complications, and improve overall quality of life. The management strategies typically involve lifestyle modifications, medications, and insulin therapy.

**1. Lifestyle Modifications:**

a. Diet: A balanced and healthy diet is essential for managing LADA. Individuals should focus on consuming whole grains, fruits, vegetables, lean proteins, and healthy fats while limiting refined carbohydrates and sugary foods. Carbohydrate counting or meal planning with the help of a registered dietitian can be beneficial to maintain stable blood sugar levels.

b. Physical Activity: Regular physical activity can improve insulin sensitivity and help manage blood glucose levels. Engaging in aerobic exercises, strength training, or any form of physical activity suitable for the individual's health status is recommended.

c. Weight Management: Achieving and maintaining a healthy weight can positively impact insulin sensitivity and glycemic control. Weight loss, if needed, should be achieved through a combination of a balanced diet and physical activity.

**2. Medications:**

The treatment of patients with Latent Autoimmune Diabetes in Adults (LADA) requires a carefully tailored approach that aims to improve metabolic control and preserve the insulin-secreting capacity of functioning beta cells. As LADA patients have functioning beta cells at the time of diagnosis, the therapeutic strategies need to consider the autoimmune nature of the condition while also addressing potential insulin resistance.

**A. Oral Hypoglycemic Agents -** Insulin Sensitizers: In the early stages of LADA, when insulin resistance is predominant, oral hypoglycemic medications commonly used in T2D may be prescribed. These may include metformin, sulfonylureas, or other insulin-sensitizing agents. However, it's essential to monitor their effectiveness, as the need for insulin therapy may arise as beta cell function declines.

a. Metformin: Metformin, a widely used oral hypoglycemic agent commonly prescribed for type 2 diabetes, may be initially used in LADA patients who are clinically misdiagnosed as having type 2 diabetes. While there is limited evidence specifically for the use of metformin in LADA, it can improve insulin sensitivity, which may be beneficial in the early stages when insulin resistance is prominent.

b. Thiazolidinediones: Thiazolidinediones (TZDs) are another class of oral hypoglycemic agents that improve insulin sensitivity. While there is less evidence for their use in LADA compared to metformin, they may be considered in select cases to address insulin resistance.

**B. Dipeptidyl Peptidase 4 Inhibitors (DPP-4i):**

DPP-4 inhibitors have shown promise in small clinical trials for patients with LADA. These medications help regulate blood glucose levels by inhibiting the enzyme responsible for breaking down incretin hormones, which promote insulin secretion and suppress glucagon release. DPP-4 inhibitors have been found to improve glycemic control and potentially preserve beta-cell function with a good safety profile in LADA patients.

**C. Immunosuppressive Agents:** In some cases, immunosuppressive medications may be considered to slow down the autoimmune destruction of beta cells. However, the use of such agents is not standard practice and requires careful consideration, as they may have significant side effects and are not universally effective.

**D. Insulin Therapy:**

As LADA progresses and beta cell function declines, insulin therapy becomes necessary to maintain optimal blood glucose control. Early initiation of insulin therapy can be beneficial to preserve remaining beta cell function and achieve better glycemic outcomes. Multiple daily injections or insulin pump therapy may be employed to mimic the body's natural insulin secretion pattern.

**3. Self-Monitoring of Blood Glucose (SMBG):**

Regular SMBG is crucial for individuals with LADA to monitor their blood glucose levels and adjust insulin doses or other medications accordingly. This helps prevent hypoglycemia and hyperglycemia and enables patients to make informed decisions about their diabetes management.

**4. Diabetes Education and Support:**

Diabetes self-management education is vital to empower individuals with LADA to understand their condition better and make informed decisions about their lifestyle and treatment. Support from healthcare professionals, diabetes educators, and support groups can also play a significant role in managing the emotional and psychological aspects of living with LADA.

**5. Regular Follow-Up:**

Regular follow-up visits with healthcare providers are essential to monitor blood glucose levels, adjust medications or insulin doses as needed, and assess for any diabetes-related complications or comorbidities.

Thus, managing LADA requires a holistic approach that considers its unique characteristics and overlaps with other types of diabetes. Lifestyle modifications, appropriate medications, and timely initiation of insulin therapy are key components of a successful management plan. By working closely with healthcare professionals and engaging in self-care, individuals with LADA can achieve better glycemic control and improve their overall well-being.

 **Conclusion**

LADA represents a significant subset of the diabetic population, with a prevalence nearly equivalent to that of type 1 diabetes. Its clinical characteristics, including adult age at onset, nonobese body type, gradual progression to insulin dependency, low C-peptide levels, and a high prevalence of GAD autoantibodies, distinguish it from other forms of diabetes. Therefore, measuring C-peptide levels and GAD autoantibodies is crucial for the accurate diagnosis of LADA.

 The presence of GAD autoantibodies in LADA suggests the involvement of an autoimmune process, similar to type 1 diabetes. Further investigations into the role of GAD autoantibodies in LADA may provide valuable insights into the pathogenesis of the disease, potentially leading to better management strategies and targeted therapies.

Overall, recognizing the distinct features of LADA is essential for prompt diagnosis and appropriate management. As our understanding of LADA advances, further research is warranted to enhance our knowledge of this condition and improve the quality of life for individuals affected by LADA.

**References**

1. Felner EI, Klitz W, Ham M, Lazaro AM, Stastny P, Dupont B, White PC. Genetic interaction among three genomic regions creates distinct contributions to early- and late-onset type 1 diabetes mellitus. Pediatr Diabetes. 2005 Dec;6(4):213-20. [PubMed]

2. Writing Group for the search for Diabetes in Youth Study Group. Dabelea D, Bell RA, D&#39; Agostino RB, Imperatore G, Johansen JM, Linder B, Liu LL, Loots B, Marcovina S, Mayer- Davis EJ, Pettitt DJ, Waitzfelder B. Incidence of diabetes in youth in the United States. JAMA. 2007 Jun 27;297(24):2716-24. [PubMed]

3. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 2001; 24:1460-7.

4. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997; 3:1288-93.

5. Hosszufalusi N, Vatay A, Rajczy K, Prohaszka Z, Pozsonyi E, Horvath L, et al. Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 2003; 26:452-7.

6. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999; 48:150-7.

7. HawaMI, Kolb H,Schloot N,et al.;Action LADA consortium. Adult-onset autoimmune diabetes in Europe is prevalent with abroad clinical phenotype: Action LADA7.Diabetes Care 2013;36

8. XiangY, HuangG, ZhuY,et al.; China National Diabetes and Metabolic Disorders Study Group. Identification of autoimmune type1diabetes and multiple organ specific auto antibodies in adult- non-insulin-requiring diabetes in China: a population based multi-center nation wide survey. Diabetes Obes Metab 2018; 21:893–7

9. Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat RevEndocrinol2017; 13:674–686

10. Cousminer DL, Ahlqvist E, Mishra R, et al. First genome-wide association study of latent autoimmune diabetes in adult srevealsnovelin sights linking immune and metabolic diabetes. DiabetesCare2018; 41:2396–2403

11. Mishra R, Åkerlund M, Cousminer D L, et al. Genetic discrimination between LADA and childhood onset type1diabetes within the MHC. Diabetes Care 2019; 43:418–425

12. Steffes MW, Sibley S, Jackson M, Thomas W. Beta cell function and the development of diabetes related complications in the diabetes control and complications trial. Diabetes Care2003; 26:832–836

13. Johansen OE, Boehm B O, Grill V, et al. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care 2014;37: e11–e12

14. Carlsson S. Etiology and pathogenesis of latent autoimmune diabetes in adults (LADA) compared to type2 diabetes. Front Physiol2019; 10:32

15. Carlsson S. Environmental (lifestyle) risk factors for LADA. Cure Diabetes Rev 2019;15:178 - 187

16.. Li H, Isomaa B,Taskinen M R,Groop L,TuomiT.Consequences of a family history of type1and type2 diabetes on the phenotype of patients with type 2 diabetes. Diabetes Care 2000; 23:589–594